Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Eli Lilly And Co (NYSE:LLY) are not likely to work against the Omicron variant of COVID-19 and their emergency use authorization has been rescinded by the U.S. Food And Drug Administration.
What Happened: The regulator said in a statement, “data show these treatments are highly unlikely to be active against the omicron variant, which is circulating at a very high frequency throughout the United States, these treatments are not authorized for use in any U.S. states, territories, and jurisdictions at this time.”
